CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 62,626 enrolled
Drug / intervention
None administered in this studybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00254995
NCT00254995N/ACompleted
CompareCT.gov

Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)

Sanofi Pasteur, a Sanofi Company·observational·Posted Nov 17, 2005·Updated Apr 19, 2016

In Brief

An observational study evaluating None administered in this study for Meningitis and Meningococcal Disease. Completed, enrolled 62,626 participants across 1 site.

Detailed Summary

To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMeningitis, Meningococcal Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 17, 2005
Enrollment StartJul 1, 2005
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 20.6 years ago

Interventions

None administered in this studybiological

N/A in this study